Sensitization to morphine induced by viral-mediated gene transfer

Science

Volumn 277, Issue 5327, 1997, Pages 812-814

  Carlezon Jr , William A ^a   Boundy, Virginia A ^a   Haile, Colin N ^a   Lane, Sarah B ^a   Kalb, Robert G ^a   Neve, Rachael L ^b   Nestler, Eric J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; GENE PRODUCT; MORPHINE;

ADAPTATION; ARTICLE; DRUG SENSITIZATION; GENE EXPRESSION; GENE TRANSFER; LOCOMOTION; MOTIVATION; PRIORITY JOURNAL; VENTRAL TEGMENTUM;

ANIMALS; CALCIUM; CONDITIONING, CLASSICAL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; INJECTIONS, SUBCUTANEOUS; MALE; MORPHINE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; REWARD; SIMPLEXVIRUS; TRANSGENES; TYROSINE 3-MONOOXYGENASE; UP-REGULATION; VENTRAL TEGMENTAL AREA;

ANIMALIA;

EID: 1842377511     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.277.5327.812     Document Type: Article

References (39)

1. P. Vezina and J. Stewart, Brain Res. 499, 108 (1989); P. W. Kalivas and J. Stewart, Brain Res. Rev. 16, 223 (1991).
2. P. Vezina and J. Stewart, Brain Res. 499, 108 (1989); P. W. Kalivas and J. Stewart, Brain Res. Rev. 16, 223 (1991).
3. B. T. Lett, Psychopharmacology 98, 357 (1989); P. V. Piazza, J.-M. Deminière, M. Le Moal, H. Simon, Science 245, 1511 (1989).
4. B. T. Lett, Psychopharmacology 98, 357 (1989); P. V. Piazza, J.-M. Deminière, M. Le Moal, H. Simon, Science 245, 1511 (1989).
5. T. E. Robinson and K. C. Berridge, Brain Res. Rev. 18, 247 (1993).
6. R. A. Wise and M. A. Bozarth, Psychol. Rev. 94, 469 (1987); G. F. Koob and F. E. Bloom, Science 242, 715 (1988).
7. R. A. Wise and M. A. Bozarth, Psychol. Rev. 94, 469 (1987); G. F. Koob and F. E. Bloom, Science 242, 715 (1988).
8. L. W. Fitzgerald, J. Ortiz, A. G. Hamedani, E. J. Nestier, J. Neurosci. 16, 274 (1996); J. Ortiz et al., Synapse 21, 289 (1995).
9. L. W. Fitzgerald, J. Ortiz, A. G. Hamedani, E. J. Nestier, J. Neurosci. 16, 274 (1996); J. Ortiz et al., Synapse 21, 289 (1995).
10. X.-F. Zhang, X.-T. Hu, F. J. White, M. E. Wolf, J. Pharmacol. Exp. Ther. 281, 699 (1997).
11. M. Hollmann, M. Hartley, S. Heinemann, Science 252, 851 (1991); P. Seeberg, Trends Neurosci. 16, 359 (1993).
12. M. Hollmann, M. Hartley, S. Heinemann, Science 252, 851 (1991); P. Seeberg, Trends Neurosci. 16, 359 (1993).
13. R. Karler, L. D. Calder, S. A. Turkanis, Brain Res. 552, 295 (1991); Y. Li et al., Psychopharmacology, in press.
14. R. Karler, L. D. Calder, S. A. Turkanis, Brain Res. 552, 295 (1991); Y. Li et al., Psychopharmacology, in press.
15. Locomotor activity was measured for 2 hours in circular chambers [M. J. D. Miserendino, X. Guitart, R. Z. Terwilliger, S. Chi, E. J. Nestler, Mol. Cell. Neurosci. 4, 440 (1993)].
16. Male Sprague-Dawley rats (325 to 350 g) were screened with morphine because of within-strain differences in drug sensitivity [V. Deroche, P. V. Piazza, M. Le Moal, H. Simon, Brain Res. 623, 341 (1993)]. This low dose of morphine is not sufficient to cause statistically significant sensitization or to increase expression of GluR1 in the VTA (W. A. Carlezon Jr. et al., unpublished data), although small increases in activity can be observed with repeated treatment (for example, Fig. 1A, left).
17. Rats were anesthetized (65 mg/kg sodium pentobarbital, intraperitoneal) and given atropine (0.25 mg/kg, s.c.) to minimize bronchial secretions. Unilateral microinjections (2.0 μl) of recombinants were delivered over 10 min into the VTA {relative to bregma: AP = -5.3, lat. = ±2.0, DV = 7.6 mm below dura [G. Paxinos and C. Watson, The Rat Brain in Strereotaxic Coordinates (Academic, Sydney, Australia, 1986)]}. The injection syringe was angled at 10° from the midline. For sham surgery, the injection syringe was lowered 1 mm into the brain. Rats were retained if the microinjection site was within the VTA.
18. 7 infectious units/ml; titers did not differ by more than 10% among preparations. Transgene expression was regulated by the constitutive promoter for the HSV immediate-early gene IE 4/5.
19. VTAs were dissected from the injected hemisphere 4 days after vector microinjection; immunoblotting was done as described (5).
20. Rats were overdosed with sodium pentobarbital and perfused with 0.9% saline followed by 4% paraformaldehyde; brains were kept overnight in 20% glycerol before slicing (40 μm, or 20 μm for double-labeling). β-Galactosidase expression was examined as described [N. Min, T. H. Joh, K. S. Kim, C. Peng, J. H. Son, Mol. Brain Res. 27, 281 (1994)].
21. F. Lim et al., Biotechniques 20, 460 (1996).
22. M. W. Jakowec, L.-H. Yen, R. G. Kalb, Neuroscience 67, 904 (1995).
23. R. L. Neve, J. R. Howe, S. Hong, R. G. Kalb, ibid. 79, 435 (1997).
24. M. T. Berhow, N. Hiroi, E. J. Nestler, J. Neurosci. 16, 4707 (1996).
25. R. M. Pruss, R. L. Akeson, M. M. Racke, J. L. Wilburn, Neuron 7, 509 (1991). Three days after surgery, fresh VTA tissue was sliced on a vibratome (300 μm) and stimulated with kainate (250 μM) for 10 min.
26. Immunohistochemical analyses for double-labeling of GluR1 and tyrosine hydroxylase were similar to those described [M. T. Berhow, N. Hiroi, L. A. Kobierski, S. E. Hyman, E. J. Nestler, J. Neurosci. 16, 8019 (1996)].
27. Immunohistochemical analysis for GluR2 (Chemicon GluR2/3; 1: 500) was similar to that described for GluR1 (76).
28. Rewarding drugs establish conditioned place preferences [R. A. Wise, in The Neuropharmacological Basis of Reward, J. M. Liebman and S. J. Cooper, Eds. (Oxford Univ. Press, Oxford, 1989)]. Place preference conditioning occurred in a three-compartment apparatus. On day 0, rats were allowed to freely explore the entire apparatus for 30 min; rats then received unilateral injections of an HSV vector or sham surgery. After 2 days' recovery, conditioning trials (two per day) were given on two consecutive days (days 3 and 4). Rats first received saline (1 ml/kg, s.c.) and were confined to a side compartment for 1 hour; 3 hours later, rats received morphine (0.5 mg/kg, s.c.) and were confined to the other side compartment for 1 hour. Compartments differed in floor texture, wall patterns, and lighting; rats do not show reliable baseline preferences for any compartment. On day 5, rats were allowed to freely explore the entire apparatus for 30 min. Rats with maximal transgene expression in the rostral VTA (from 4.7 to 5.3 mm posterior to bregma) were included.
29. D. Galey, H. Simon, M. Le Moal, Brain Res. 124, 83 (1977).
30. M. J. During, J. R. Naegele, K. L. O'Malley, A. I. Geller, Science 266, 1399 (1994).
31. O. Isacson, ibid. 269, 856 (1995).
32. R. L. Neve and A. I. Geller, Clin. Neurosci. 3, 1 (1996); D. J. Fink, N. A. DeLuca, W. F. Goins, J. C. Glorioso, Annu. Rev. Neurosci. 19, 265 (1996).
33. R. L. Neve and A. I. Geller, Clin. Neurosci. 3, 1 (1996); D. J. Fink, N. A. DeLuca, W. F. Goins, J. C. Glorioso, Annu. Rev. Neurosci. 19, 265 (1996).
34. M. A. Bozarth and R. A. Wise, Life Sci. 28, 551 (1981).
35. D. W. Self and E. J. Nestler, Annu. Rev. Neurosci. 18, 463 (1996); L. Sklair-Tavron et al., Proc. Natl. Acad. Sci. U.S.A. 93, 11202 (1996).
36. D. W. Self and E. J. Nestler, Annu. Rev. Neurosci. 18, 463 (1996); L. Sklair-Tavron et al., Proc. Natl. Acad. Sci. U.S.A. 93, 11202 (1996).
37. D. S. Segal and R. Kuczenski, Brain Res. 577, 351 (1992).
38. D. J. Henry and F. J. White, J. Neurosci. 15, 6287 (1995).
39. Supported by grants (to E.J.N.) and a fellowship (to W.A.C.) from the National Institute on Drug Abuse (USA), and grants (to R.G.K. and R.L.N.) from the National Institutes of Health. We thank N. Hiroi for his contributions.